Welcome to our dedicated page for Moolec Science SA SEC filings (Ticker: MLECW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moolec Science SA files as a foreign private issuer, and its regulatory documents disclose the business, governance, and capital structure of a science-based food ingredient company focused on scalable protein solutions. Its Form 6-K reports and related exhibits cover annual general meeting materials, consolidated financial statements, board composition, registration-statement incorporation, and shareholder voting matters.
The filings also document completed capital-structure and control developments, including preference-share conversion into ordinary shares and the emergence of a controlling shareholder. Other disclosures address Nasdaq listing compliance, a completed reverse stock split, Form 20-F reporting, S-8 registration context, and governance practices applicable to the company’s public securities.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.
Moolec Science SA director Leon Bentancor Oscar Alejandro filed an initial Form 3 reporting option-based holdings in the company’s ordinary shares. He holds three direct share option positions, each with an exercise price of 7.1400 per share, covering 934, 933 and 933 ordinary shares with expirations in 2031, 2032 and 2033.
Moolec Science SA director Leon Bentancor Oscar Alejandro filed an initial Form 3 reporting option-based holdings in the company’s ordinary shares. He holds three direct share option positions, each with an exercise price of 7.1400 per share, covering 934, 933 and 933 ordinary shares with expirations in 2031, 2032 and 2033.
Moolec Science SA reported the initial holdings of its General Counsel, Gloria Montaron Estrada, in a Form 3. She directly holds 1,909 ordinary shares of the company as of the reported date, and the filing does not record any new share purchases or sales.
Moolec Science SA reported the initial holdings of its General Counsel, Gloria Montaron Estrada, in a Form 3. She directly holds 1,909 ordinary shares of the company as of the reported date, and the filing does not record any new share purchases or sales.
Moolec Science SA reported changes to its Board of Directors. Daniel Core has been appointed to the Board, effective February 25, 2025, and will also serve on the Audit Committee and the Compensation Committee. On the same date, directors Aimar Dimo and Gloria Montaron Estrada resigned from the Board. The company thanked both departing directors for their service. Moolec Science focuses on engineering plants and microbes to produce scalable protein ingredients for the global food system and is listed on Nasdaq under the ticker MLEC.
Moolec Science SA reported changes to its Board of Directors. Daniel Core has been appointed to the Board, effective February 25, 2025, and will also serve on the Audit Committee and the Compensation Committee. On the same date, directors Aimar Dimo and Gloria Montaron Estrada resigned from the Board. The company thanked both departing directors for their service. Moolec Science focuses on engineering plants and microbes to produce scalable protein ingredients for the global food system and is listed on Nasdaq under the ticker MLEC.
Moolec Science received a decision from a Nasdaq Hearings Panel allowing its shares to remain listed on the Nasdaq Capital Market, subject to specific conditions. The Panel found that Moolec regained compliance with the minimum bid price rule on January 16, 2026, after a reverse stock split that became effective on January 5, 2026.
The Panel noted that Moolec filed its Annual Report on Form 20-F for the year ended June 30, 2025, on December 29, 2025, and accepted the company’s plan to address the minimum stockholders’ equity requirement. Continued listing depends on Moolec providing derecognition updates by the end of February 2026, updated pro forma financial information by the end of March 2026, timely public disclosure of actions to demonstrate equity compliance by May 13, 2026, and full compliance with all Nasdaq Capital Market continued listing standards by May 13, 2026.
Moolec Science received a decision from a Nasdaq Hearings Panel allowing its shares to remain listed on the Nasdaq Capital Market, subject to specific conditions. The Panel found that Moolec regained compliance with the minimum bid price rule on January 16, 2026, after a reverse stock split that became effective on January 5, 2026.
The Panel noted that Moolec filed its Annual Report on Form 20-F for the year ended June 30, 2025, on December 29, 2025, and accepted the company’s plan to address the minimum stockholders’ equity requirement. Continued listing depends on Moolec providing derecognition updates by the end of February 2026, updated pro forma financial information by the end of March 2026, timely public disclosure of actions to demonstrate equity compliance by May 13, 2026, and full compliance with all Nasdaq Capital Market continued listing standards by May 13, 2026.
Moolec Science S.A. received a decision from a Nasdaq Hearings Panel granting an exception through June 29, 2026 to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The company reports that the bankruptcy of certain subsidiaries triggered loss-of-control derecognition events under IFRS, leading to estimated gains of approximately $91.0 million for Bioceres S.A., $5.2 million for Bioceres LLC, and $4.6 million for Theo I SCSp.
Together with recognition of intercompany assets and liabilities and conversion of certain preference shares into ordinary shares, these items increased Moolec’s stockholders’ equity. Based on this, Moolec believes it has regained compliance with Nasdaq’s equity standard and has notified Nasdaq, while stating it will continue taking actions to maintain ongoing listing compliance.
Moolec Science S.A. received a decision from a Nasdaq Hearings Panel granting an exception through June 29, 2026 to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The company reports that the bankruptcy of certain subsidiaries triggered loss-of-control derecognition events under IFRS, leading to estimated gains of approximately $91.0 million for Bioceres S.A., $5.2 million for Bioceres LLC, and $4.6 million for Theo I SCSp.
Together with recognition of intercompany assets and liabilities and conversion of certain preference shares into ordinary shares, these items increased Moolec’s stockholders’ equity. Based on this, Moolec believes it has regained compliance with Nasdaq’s equity standard and has notified Nasdaq, while stating it will continue taking actions to maintain ongoing listing compliance.
Moolec Science SA completed corporate restructuring and a major acquisition combining several agtech entities while disclosing significant financing stress.
The company implemented a 10-for-1 reverse stock split and redomiciled from Luxembourg to the Cayman Islands, with fractional shares rounded up and all per-share data adjusted for the Consolidation Ratio. On June 16, 2025 Moolec closed a Business Combination that made it legal parent of Bioceres Group, Gentle Tech and Nutrecon; the EGM had 77% attendance and the transaction received 98% of votes cast. IFRS 3 treats Bioceres Group Limited as the accounting acquirer.
Post-closing amendments to secured notes for Bioceres Crop Solutions led to loss of de facto control and deconsolidation; the leverage covenant was revised to 5x and maturity extended to August 31, 2027. Bioceres S.A. initiated a debt restructuring for $36.4 million and Bioceres LLC received a $69.5 million default notice and auction of 3,062,500 pledged BIOX shares. Management cites a material uncertainty about the Group’s ability to continue as a going concern and describes plans to restructure debt, seek investor financing and operate a Restructuring Committee.